TrialHead & neck2019
MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis.
Olga Rodriguez Cabo Beltran et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
11 papers cite it
this papertrialcites it